Back

Impact of Pirfenidone on arrhythmic and clinical outcomes in patients with idiopathic pulmonary fibrosis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: From cellular mechanisms to arrhythmias in non-cardiac diseases Prevention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Sung Il Im

kosin university gospel hospital, Pusan (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
Arrhythmogenic effects of DEHP exposure: insights into cardiac electrophysiology and myocardial cells
Doctor T. Lin (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Mitochondrial Oxidative Stress and Cardiac Dysfunction in TERT Knockout Mice
Professor T. Liu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
The Mutscore metapredictor: a new application of artificial intelligence in cardiogenetics
Doctor A. Porretta (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Comprehensive risk factor analysis for sick sinus syndrome: an analysis of genetic, sociodemographic, clinical and laboratory data from the UK Biobank.
Doctor H. Kim (Ulsan, KR)
Abstract Slides Video
Presentation thumbnail
Impact of SLGT2 inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac defibrillator
Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides Video

Access the full session

Session thumbnail
From cellular mechanisms to arrhythmias in non-cardiac diseases

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Impact of Pirfenidone on arrhythmic and clinical outcomes in patients with idiopathic pulmonary fibrosis
thumbnail
Congress Presentation
Altered fibrin clot properties and elevated von Willebrand Factors level are associated with progression to permanent atrial fibrillation during follow-up: a cohort study
thumbnail
Congress Presentation
Employing epi-drugs to rescue lung microenvironmental changes in heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources